Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers

S. K. Jin, H. J. Chung, M. W. Chung, J. I. Kim, J. H. Kang, S. W. Woo, S. Bang, S. H. Lee, H. J. Lee, J. Roh

Research output: Contribution to journalArticlepeer-review

40 Scopus citations


Background and objective: Genetic polymorphism of CYP2D6 leads to differences in pharmacokinetics of CYP2D6 substrates. The CYP2D6*10 allele is clinically important in Koreans because of its high frequency in Asians. We investigated whether the pharmacokinetics of metoprolol was altered by the presence of the CYP2D6*10 allele in Korean subjects. Methods: One hundred and seven volunteers were recruited and grouped as CYP2D6*1/*1, CYP2D6*1/*10 and CYP2D6*10/*10 according to their genotypes. Metoprolol tartrate 100 mg (Betaloc®) was administered orally once to each subject in these three groups (n = 6, 7 and 5, respectively). The pharmacokinetic parameters of metoprolol and its metabolite, α-hydroxymetoprolol, and the metabolic ratio for the three groups were estimated and compared. Results and discussion: The area under the plasma concentration-time curve (AUC0→∞), the maximum plasma concentration (Cmax) and the elimination half-life (T1/2) of metoprolol and α-hydroxymetoprolol for the CYP2D6*10/*10 group were all significantly different from those of the CYP2D6*1/*1 group (P < 0.05). The AUC0→∞s of metoprolol were 443.7 ± 168.1, 995.6 ± 321.4 and 2545.3 ± 632.0 ng.h/mL, and the AUC0→∞s of α-hydroxymetoprolol were 1232.0 ± 311.2, 1344.0 ± 288.1 and 877.4 ± 103.4 ng.h/mL for groups CYP2D6*1/*1, *1/*10 and *10/*10, respectively. The corresponding T1/2 values of metoprolol were 2.7 ± 0.5, 3.2 ± 1.3 and 5.0 ± 1.1 h, while those of α-hydroxymetoprolol were 5.4±1.5, 6.0 ± 1.4 and 10.5 ± 4.2 h, respectively. The metabolic ratios of the three groups were significantly different (P < 0.05). Conclusion: The CYP2D6*10 allele altered the pharmacokinetics of metoprolol in Korean subjects and is likely to affect other drugs metabolized by the CYP2D6 enzyme, similarly.

Original languageEnglish
Pages (from-to)567-573
Number of pages7
JournalJournal of Clinical Pharmacy and Therapeutics
Issue number5
StatePublished - Oct 2008


  • CYP2D6
  • Korean
  • Metoprolol
  • Pharmacokinetics


Dive into the research topics of 'Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers'. Together they form a unique fingerprint.

Cite this